INT24080

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1987
Last Reported 2011
Negated 0
Speculated 2
Reported most in Body
Documents 64
Total Number 67
Disease Relevance 41.56
Pain Relevance 5.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Mtor) mitochondrion (Mtor) Golgi apparatus (Mtor)
endoplasmic reticulum (Mtor) nucleus (Mtor) kinase activity (Mtor)
Anatomy Link Frequency
myocardium 1
primary neurons 1
muscle fibers 1
skin 1
face 1
Mtor (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 34 100.00 Very High Very High Very High
Somatostatin 6 100.00 Very High Very High Very High
COX-2 inhibitor 1 100.00 Very High Very High Very High
substance P 1 100.00 Very High Very High Very High
antagonist 32 99.96 Very High Very High Very High
ischemia 77 99.84 Very High Very High Very High
c fibre 6 99.36 Very High Very High Very High
qutenza 17 97.32 Very High Very High Very High
positron emission tomography 125 96.36 Very High Very High Very High
cva 48 91.08 High High
Disease Link Frequency Relevance Heat
Cancer 1097 99.84 Very High Very High Very High
Cv Unclassified Under Development 181 99.84 Very High Very High Very High
Hepatocellular Cancer 424 99.78 Very High Very High Very High
Frailty 17 99.60 Very High Very High Very High
Epilepsy 24 99.48 Very High Very High Very High
Renal Cancer 335 99.44 Very High Very High Very High
Cognitive Disorder 9 99.44 Very High Very High Very High
Hypertrophy 43 99.24 Very High Very High Very High
Stress 343 99.22 Very High Very High Very High
Autosomal Dominant Polycystic Kidney 227 99.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The reduction in the level of TBARS and increase in FRAP were significantly higher in the antioxidant group compared with the placebo group (TBARS: placebo 1.2+/-2.7 vs antioxidant 3.5+/-3.4 nmol/mL; P= .001; 95% CI 0.96, 3.55; FRAP: placebo -5.6+/-154.9 vs antioxidant 97.8+/-134.9 microMFe(+2) liberated, P= .001, 95% CI 44.98, 161.7).
Negative_regulation (reduction) of FRAP
1) Confidence 0.37 Published 2009 Journal Gastroenterology Section Body Doc Link 18952082 Disease Relevance 0.16 Pain Relevance 0
These include depletion of the enzyme FRAP and the peptides SP, CCK, somatostatin, CGRP and an increase of VIP.
Negative_regulation (depletion) of FRAP associated with somatostatin
2) Confidence 0.16 Published 1987 Journal Acta Physiol Hung Section Abstract Doc Link 3310519 Disease Relevance 0 Pain Relevance 0.66
We found that the rapamycin analogue CCI-779, which induces autophagy by inhibiting the protein kinase mTOR (mammalian target of rapamycin), improved behavioural performance and decreased aggregate formation in a mouse model of HD (14) and in a mouse model of another polyglutamine disease, spinocerebellar ataxia type 3 (15).
Negative_regulation (inhibiting) of mTOR associated with machado-joseph disease and disease
3) Confidence 0.12 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2865373 Disease Relevance 0.72 Pain Relevance 0.07
Further analysis of the effects of rilmenidine on primary neurons confirmed that rilmenidine does not act to upregulate autophagy via inactivation of the mTOR pathway.
Negative_regulation (inactivation) of mTOR in primary neurons
4) Confidence 0.10 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2865373 Disease Relevance 0.13 Pain Relevance 0
Downregulation of the translation regulatory signaling pathways via PI3K/Akt/mTOR in Ames mice provides evidence of the decreased protein synthesis, lack of growth, and, potentially, the decreased incidence of cancer in the face of increased food consumption (Sharp and Bartke 2005).
Negative_regulation (Downregulation) of mTOR in face associated with cancer
5) Confidence 0.06 Published 2006 Journal Age (Dordr) Section Body Doc Link PMC2464727 Disease Relevance 0.73 Pain Relevance 0
Inhibition of mTor by nutrient reduction or by activation of PI3K results in activation of the Atg kinase 1 that in turn phosphorylates Atgs that participate in the AV formation [71], [72], [73].
Negative_regulation (Inhibition) of mTor
6) Confidence 0.05 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824828 Disease Relevance 1.06 Pain Relevance 0
Alternatively, reduced mitochondrial function may also inactivate mTOR activity[37], however further studies are needed to clarify this issue.
Spec (may) Negative_regulation (inactivate) of mTOR
7) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2794538 Disease Relevance 0.34 Pain Relevance 0.03
It is possible that the activation of AMPK induced by the raise in the AMP:ATP relative amount may inhibit the mTOR/S6K complex in the overloaded myocardium[32].
Spec (may) Negative_regulation (inhibit) of mTOR in myocardium
8) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2794538 Disease Relevance 0.27 Pain Relevance 0.03
The data from the present study indicate that MEF2C depletion is accompanied by downregulation of the mTOR/S6K pathway [32], [33] [34].
Negative_regulation (downregulation) of mTOR
9) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2794538 Disease Relevance 0.21 Pain Relevance 0
Effects of 48 h combined inhibition of MEK and mTOR on tumour proliferation
Negative_regulation (inhibition) of mTOR associated with cancer
10) Confidence 0.05 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2955043 Disease Relevance 0.37 Pain Relevance 0
This study supports the notion that defects in the autophagy pathway and more specifically in mTor and Atg7 are associated with neurodegeneration in DLB cases and ?
Negative_regulation (defects) of mTor associated with parkinson's disease
11) Confidence 0.04 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2824828 Disease Relevance 0.98 Pain Relevance 0
In addition, the reduction in PI3K and mTOR signaling and subsequent attenuation of anabolism may simulate a stressful situation and upregulate general defense and repair systems, which, in the long term, extend lifespan.
Negative_regulation (reduction) of mTOR associated with lifespan
12) Confidence 0.04 Published 2006 Journal Age (Dordr) Section Body Doc Link PMC2464727 Disease Relevance 0.75 Pain Relevance 0
The inhibition of mTOR induces cell cycle arrest in G1 phase [7, 8].
Negative_regulation (inhibition) of mTOR
13) Confidence 0.04 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2719751 Disease Relevance 1.28 Pain Relevance 0.08
-syn tg mice might be in part related to increased levels of mTor, we investigated whether blocking mTor with rapamycin might promote ?
Negative_regulation (blocking) of mTor
14) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824828 Disease Relevance 0.19 Pain Relevance 0.03
Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of ?
Negative_regulation (inhibitor) of mTor
15) Confidence 0.04 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2824828 Disease Relevance 1.43 Pain Relevance 0
Moreover, a recent study showed that blocking mTor by overexpression of the translation inhibitor Thor (4E-BP) can reduce the pathologic features in PD models, including degeneration of dopaminergic neurons in Drosophila [81].
Negative_regulation (blocking) of mTor in dopaminergic neurons associated with disease
16) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824828 Disease Relevance 0.86 Pain Relevance 0
The findings from other studies using 18F-FLT PET to assess early responses to anti-cancer treatment have been very variable, where response to a histone deacetylase inhibitor was observed after 4 days [10], response to cisplatin is seen after 1 day [9], response to cyclophosphamide and mTOR inhibition is evident after 2 days [16] and the ErbB kinase inhibitor initiated a decrease in 18F-FLT uptake 2 days after treatment initiation whereas no response was observed at 6 and 24 hours [11].
Negative_regulation (inhibition) of mTOR associated with positron emission tomography and immunotherapy of cancer
17) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2945761 Disease Relevance 0.39 Pain Relevance 0.11
Top001 inhibits the mTOR pathway in a cell-selective manner after prolonged incubation (?
Negative_regulation (inhibits) of mTOR
18) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2945761 Disease Relevance 1.06 Pain Relevance 0.11
They administered an inhibitor of mTOR, RAD001 (everolimus), to the knock-in mice.
Negative_regulation (inhibitor) of mTOR associated with targeted disruption
19) Confidence 0.04 Published 2009 Journal World J Surg Oncol Section Body Doc Link PMC2749031 Disease Relevance 0.77 Pain Relevance 0
Our results clearly illustrate that pharmacological inhibition of the mTOR with rapamycin and specific targeting of VEGF with bevacizumab may provide an effective novel treatment for HCC.
Negative_regulation (inhibition) of mTOR associated with hepatocellular cancer
20) Confidence 0.04 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2719751 Disease Relevance 0.56 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox